Group structure
5 companies in 5 countries
Canada1
Germany1
United Kingdom1
United States1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loading…
5 companies in 5 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
20 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABELCET5mg/ml · Injectable, lipid complex | Amphotericin b | United States | Not marketed | 1995 |
| ÁCIDO QUENODESOXICÓLICO LEADIANT 250 MG CÁPSULAS DURAS250 mg mg · Cápsula dura | Quenodesoxicolico acido | Spain | Marketed | 2019 |
| ADAGEN250 units/ml · Injectable | Pegademase bovine | United States | Not marketed | 1990 |
| CARNITOR200 mg / ml · Solution | Levocarnitine | Canada | Marketed | 1995 |
| CARNITOR100 mg / ml · Solution | Levocarnitine | Canada | Marketed | 1995 |
| CARNITOR330 mg · Tablet | Levocarnitine | Canada | Marketed | 1995 |
| CARNITOR1gm/10ml · Solution | Levocarnitine | United States | Marketed | 1985 |
| CARNITOR200mg/ml · Injectable | Levocarnitine | United States | Marketed | 1992 |
| CARNITOR330mg · Tablet | Levocarnitine | United States | Marketed | 1985 |
| CARNITOR SF1gm/10ml · Solution | Levocarnitine | United States | Marketed | 1986 |
| CHENIX250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Chenodiol | United States | Not marketed | 1983 |
| Chenodeoxycholic acid Leadiant 250 mg harde capsulesCapsule, hard | Chenodeoxycholic acid | Netherlands | Authorised | 2017 |
| Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) | Chenodeoxycholic acid | EU (EMA) | Authorised | 2017 |
| CYSKLAR0.44 % w/v · Solution | Cysteamine | Canada | Authorised | |
| CYSTARAN0.44% base · Solution/drops | Cysteamine | United States | Marketed | 2012 |
| MATULANE50mg base · Capsule | Procarbazine | United States | Marketed | 1969 |
| MATULANE50 mg · Capsule | Procarbazine | Canada | Marketed | 1970 |
| NATULAN 50 MG CÁPULAS DURAS50 mg · Cápsula dura | Procarbazine | Spain | Marketed | 1965 |
| Natulan, capsules, hard 50 mgCapsule, hard | Procarbazine | Netherlands | Authorised | 1966 |
| ABELCET5 mg / ml · Suspension | Amphotericin b | Canada | Cancelled | 1997 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 9 | 9 | 0 | CompaniesAll medicines |
| Canada | 6 | 5 | 1 | CompaniesAll medicines |
| Spain | 2 | 2 | 0 | CompaniesAll medicines |
| Netherlands | 2 | 2 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Colombia, France, Italy, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Contains Irish Public Sector Data licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), Companies Registration Office; original dataset/API URL and company number, exact locator/source version and retrieval date; selected field normalization by Prognia. https://creativecommons.org/licenses/by/4.0/
Licence: Creative Commons Attribution
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Leadiant’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.